Home Tags AbbVie

Tag: AbbVie

World ADC 2018 Highlights

What to Expect at World ADC 2024 in London

What to Expect at World ADC 2024 in London

Creating A Strong ADC Pipeline: AbbVie Agrees to Acquires ImmunoGen for...

Creating A Strong ADC Pipeline: AbbVie Agrees to Acquires ImmunoGen for $10.1 Billion

AbbVie Discontinues Research and Development Program for Rovalpituzumab Tesirine

MERU, a Phase III trial evaluating rovalpituzumab tesirine (Rova-T / SC16LD6.5; AbbVie) as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated...

Depatuxizumab Mafodotin Did Not Demonstrate Survival Benefit in INTELLANCE-1 Study

Depatuxizumab mafodotin (also known as Depatux-M, and previously known as ABT-414), an antibody-drug conjugate (ADC) being developed by AbbVie, did not demonstrate a survival...

Researchers Find SCLC-biopsy Specimen Reliable for Evaluating DLL3 Expression

High levels of delta-like protein 3 or DLL3 in small-cell lung cancer or SCLC are correlated with poor survival trends.  Li-Xu Yan, MD, a...

AbbVie and Bristol-Myers Squibb Evaluate Telisotuzumab Vedotin and Nivolumab in c-Met...

A new clinical trial collaboration between AbbVie and Bristol-Myers Squibb Company will evaluate the combination of AbbVie's investigational antibody-drug conjugate telisotuzumab vedotin also known...

Antibody-drug Conjugates: Technologies and Global Markets

Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new.  Due to many technological advances, recognition of appropriate target antigens, success...

Rovalpituzumab tesirine: Most Promising Clinical Candidate

Rovalpituzumab tesirine, also known as Rova-T, an antibody-drug conjugate being developed by AbbVie/Stemcentrx was recognized at the 7th Annual World Antibody Drug Conjugate (ADC)...

Rare Pediatric Disease Designation for ABT-414 for the Treatment of a...

The U.S. Food and Drug Administration (FDA) has a granted Rare Pediatric Disease Designation for AbbVie's ABT-414, an investigational antibody-drug conjugate (ADC) targeting the...

ABT-414 Shows Encouraging Phase I Results in Monotherapy in Patients with...

Safety and preliminary efficacy data from a phase I study of ABT-414 (AbbVie) – an investigational antibody drug conjugate or ADC for the treatment of...

X